FAPI74

Digestive System Cancer

SOFIESmall moleculePhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 89/ 100

Competitive context

72 Active assets in the Digestive System Cancer cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Amgen	Phase 2	BB
Fluorouracilum Alliance for Clinical Trials in Oncology	Phase 2	BB
Dexasone Cedars-Sinai Medical Center	Phase 4	BB
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Brian Anderson, MD	Phase 4	BB
Mlf 541 B. Braun Melsungen AG	Phase 3	BB

View all 50 →

Same molecule, other indications

FAPI74 is also rated in:

cholangiocarcinomaActive

CCC

Indicative · Phase 2

54 / 100

invasive lobular breast carcinomaActive

CCC

Indicative · Phase 2

53 / 100

small cell lung carcinomaActive

CCC

Indicative · Phase 2

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.